

## **1.3.1**

# **Summary of Product Characteristics (SmPC)**

## Module-1 Administrative Information and Product Information

### 1. Name of the medicinal Product

#### 1.1 Name of the medicinal Product

Metformin Tablets BP

#### 1.2 Strength

Each Film Coated Tablet contains:

Metformin Hydrochloride BP 500 mg

Excipients Q.S.

### 2. Qualitative and Quantitative Composition

#### 2.1 Qualitative Declaration

Metformin Hydrochloride BP

#### 2.2 Quantitative Declaration

Sr. No.	Ingredients	Specifications	Label Claim (mg/tablet)	Function
1	Metformin Hydrochloride	BP	500.00	Anti-diabetics agent
2	Povidone (PVPK-90)	BP	5.00	Binder
3	Crosscarmellose Sodium	USP-NF	5.00	Disintegrant
4	Colloidal Anhydrous Silica (Aerosil)	BP	10.00	Glidant
5	Crosscarmellose Sodium	USP-NF	12.00	Disintegrant
6	Purified Talc	BP	10.00	Glidant
7	Microcrystalline Cellulose (pH 102)	BP	28.00	Diluent
8	Magnesium Stearate	BP	5.00	Lubricant
9	Colour White SC-SP 3180 (Spraycel)	BP	18.00	Colouring agent
10	Purified Water	BP	Q.S.	Binding Solvent

### 3. Pharmaceutical Form



## **Module-1 Administrative Information and Product Information**

---

Film Coated Tablet.

White to off-white coloured, round shaped, biconvex, film coated tablets, plain on both side.

### **4. Clinical Particulars**

#### **4.1 Therapeutic Indications**

Metformin hydrochloride tablets are indicated for the management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as monotherapy when hyperglycemia cannot be managed with diet and exercise alone. In adults, may be used concomitantly with a sulfonylurea or insulin to improve glycaemic control.

#### **4.2 Posology and Method of Administration**

There is no fixed dosage regimen for the management of hyperglycemia in patient with type 2 diabetes with Metformin hydrochloride tablets. Dosage of Metformin hydrochloride tablets should be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose for Metformin hydrochloride tablet is 2550 mg for adult and 2000 mg for children (10-16 years of age).

**Adult:** Initial 500 mg twice daily or 850 mg once daily; titrate in increments of 500 mg weekly or 850 mg every other week; may also titrate from 500 mg twice a day to 850 mg twice a day after 2 weeks with breakfast or first main meal of the day and gradual increased dosage as directed by physician.

**Children 10-16 years:** Initial: 500 mg twice daily; increases in daily dosage should be made in increments of 500 mg at weekly intervals, given in divided doses, up to a maximum of 2000 mg/day.

#### **4.3 Contraindications**

Metformin hydrochloride tablets are contraindicated for patient with Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels 1.5 mg/dL [males], 1.4 mg/dL [females] or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia.

Known hypersensitivity to Metformin, or any of the ingredients of the Metformin Hydrochloride tablets.



## Module-1 Administrative Information and Product Information

Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.

Diabetic ketoacidosis should be treated with insulin.

Temporarily discontinue in patients undergoing radiologic studies in which intravascular iodinated contrast media are utilized, because use of such products may result in acute alteration of renal function.

### 4.4 Special Warnings and Special Precautions for Use

Use Metformin hydrochloride with caution in patients with Cardiovascular mortality as oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin.

Lactic acidosis is a rare, but potentially severe consequence of therapy with Metformin.

**Hepatic impairment:** Avoid use in patients with impaired liver function due to potential for lactic acidosis.

**Renal impairment:** Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy.

**Elderly:** Metformin should not be initiated in patient > 80 years of age unless normal renal function is confirmed.

**Stress-related states:** It may be necessary to discontinue Metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).

**Pregnancy:** Available information suggests that Metformin use during pregnancy may be safe as long as good glycaemic control is maintained. Metformin Hydrochloride is prescribed unlabeled for the treatment of Gestational Diabetes Mellitus (GDM); Polycystic Ovary Syndrome (PCOS). However the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Metformin hydrochloride tablets should not be used unless the potential benefit outweighs the potential risk to fetus.

**Lactation:** Metformin Hydrochloride tablets are not recommended for use in lactating mothers as it excretes into breast milk.

### 4.5 Interaction with other medicinal products and other forms of interaction

Drug	Interaction
------	-------------

**Module-1 Administrative Information and Product Information**

Amiloride, Digoxin, Morphine, Procainamide, Quinidine, Quinine, Ranitidine, Triamterene, Vancomycin	Compete with Metformin hydrochloride for substantial tubular secretion
ACE inhibitors	Potential risk of hypoglycemia /hyperglycemia when ACE inhibitor therapy is initiated/withdrawn
Calcium-channel blocking agents, corticosteroids, thiazide diuretics, estrogens and progestins (e.g., oral contraceptives), isoniazid, niacin, phenothiazines, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline)	Antagonize Hypoglycemic Effects of Metformin in hydrochloride
Alcohol	Increased risk of hypoglycemia and lactic acidosis
Cimetidine	Possible decreased excretion of Metformin hydrochloride
Clomiphene	Possible resumption of ovulation in premenopausal patients with polycystic ovary syndrome
Furosemide	Increased plasma concentrations of Metformin in hydrochloride and furosemide
Glyburide	Variable decreases in AUC and peak blood concentration of Glyburide
Nifedipine	Enhanced absorption and increased urinary excretion of Metformin
Thiazide diuretics	May exacerbate diabetes mellitus

**4.6 Fertility, Pregnancy and Lactation**

**Pregnancy:** Available information suggests that Metformin use during pregnancy may be safe as long as good glycaemic control is maintained. Metformin Hydrochloride is prescribed unlabeled for the treatment of Gestational Diabetes Mellitus (GDM); Polycystic Ovary

## **Module-1 Administrative Information and Product Information**

---

Syndrome (PCOS). However the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Metformin hydrochloride tablets should not be used unless the potential benefit outweighs the potential risk to fetus.

**Lactation:** Metformin Hydrochloride tablets are not recommended for use in lactating mothers as it excretes into breast milk.

### **4.7 Effects on ability To Drive and use Machines**

No studies on the effects on the ability to drive and use machines have been performed.

### **4.8 Undesirable Effects**

**Gastrointestinal:** Diarrhea, nausea, vomiting, flatulence Indigestion, abdominal discomfort, abdominal distention, abnormal stools, constipation, dyspepsia/ heartburn, taste disorder

**Neuromuscular & skeletal:** Weakness, Myalgia

**Cardiovascular:** Chest discomfort, flushing, palpitation

**Central Nervous System:** Headache, chills, dizziness, light headedness

**Dermatologic:** Rash

**Endocrine& Metabolic:** Hypoglycemia

**Respiratory:** Dyspnea, upper respiratory tract infection

**Miscellaneous:** Diaphoresis increased, vitamin B 12 levels decreased, flu-like syndrome, nail disorder.

### **4.9 Overdose**

Mild hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid IV injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, because hypoglycemia may recur after apparent clinical recovery.



## **Module-1 Administrative Information and Product Information**

---

Lactic acidosis is a rare, but serious, metabolic complication that can occur if Metformin accumulates during treatment due to overdosing. Strict monitoring should be continued until the doctor is sure that the patient is out of danger.

### **5. Pharmacological Properties**

#### **5.1 Pharmacodynamics Properties**

Oral Anti-diabetic Agent

Metformin hydrochloride decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization).

#### **5.2 Pharmacokinetic Properties**

**Onset of action:** Within days; maximum effects up to 2 weeks

**Distribution:** Vd:  $654 \pm 358$  L; partitions into erythrocytes

**Protein binding:** Negligible

**Metabolism:** Not metabolized by the liver

**Bioavailability:** Absolute: Fasting: 50% to 60%

**Half-life elimination:** Plasma: 4-9 hours

**Time to peak, serum:** Extended release: 7 hours (range: 4-8 hours)

**Excretion:** Urine (90% as unchanged drug; active secretion)

#### **5.3 Preclinical Safety Data**

Not Applicable

### **6 Pharmaceutical Particulars**

#### **6.1 List of Excipients**

Povidone (PVPK-90) BP

Crosscarmellose Sodium USP-NF

Purified Talc BP

Colloidal Anhydrous Silica BP

Microcrystalline Cellulose (PH 102) BP

Magnesium Stearate BP



## **Module-1 Administrative Information and Product Information**

---

Colour White SC-SP 3180 (Spraycel) BP

Purified Water BP

### **6.2 Incompatibilities**

None.

### **6.3 Shelf Life**

36 months

### **6.4 Special Precautions for Storage**

Store below 30<sup>0</sup>C. Protect from light.

### **6.5 Nature and Contents of Container**

White to off-white coloured, round shaped, biconvex, film coated sustained release tablets, plain on both sides. 10 tablets are packed in Alu-PVC blister pack. 3 blisters are packed in printed carton along with packaging insert.

### **6.6 Special precaution for disposal and other handling**

Any unused product or waste material should be disposed of in accordance with local requirements.

## **7. Registrant (Marketing Authorization Holder And Manufacturing Site Addresses)**

### **7.1 Name and Address of Marketing Authorization Holder**

**GENERICIS AND SPECIALITIES LTD.**

31, AWONIYI ELEMO STREET,

OFF LATEEF SALAMI STREET.

AJAO ESTATE, LAGOS,

NIGERIA.

E-mail: [info@zolonhealthcare.com](mailto:info@zolonhealthcare.com)

### **7.2 Name and Address of manufacturing site(s)**

Lincoln Pharmaceuticals Limited





## **Module-1 Administrative Information and Product Information**

---

Trimul Estate, Khatraj, Taluka: Kalol,

District: Gandhinagar Gujarat, India.

Telephone no.: +91-07949-135000

Fax: +91-07941-078062

Email: [info@lincolnpharma.com](mailto:info@lincolnpharma.com)

Website: [www.lincolnpharma.com](http://www.lincolnpharma.com)

### **7.3 Marketing Authorization Number**

To be included after obtaining first registration.

### **7.4 Date of First <Registration> / Renewal of The <Registration>**

It will be applicable after registration of this product.

### **8. Date of Revision of the Text**

----

### **9. Dosimetry (If Applicable)**

Not Applicable

### **10. Instructions for preparation of radiopharmaceuticals (if Applicable)**

Not Applicable